Navigation Links
PRA International Speaking Event: Beyond Global Feasibility
Date:3/19/2009

An Evidence-Based Approach to Creating Realistic Development Timelines

RALEIGH, N.C., March 19 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces its Senior Vice President of Scientific and Medical Affairs, Kent Thoelke, will host a webinar on optimizing site and country selection. The webinar will take place on March 25, 2009 at 11:30 am ET.

Mr. Thoelke will discuss how to mitigate one of the greatest risks for successful drug development: delayed clinical development timelines. Detailed planning and appropriate site and country selection are the most critical factors in meeting target patient accrual goals within the planned timeline. Mr. Thoelke will explore how an evidence-based approach, coupled with survey based feasibility provides the most accurate forecast for patient accrual and the selection of sites and countries with the highest likelihood of being productive.

With PRA since 2006, Mr. Thoelke has over 19 years of experience in the global drug development and device industry, holding positions in both clinical and corporate development in multinational R&D companies, as well as small and emerging biotechnology companies. As part of the PRA Leadership Team, Mr. Thoelke provides high-level strategic oversight of product development, supporting PRA teams that are executing studies for Sponsors. Having visited over 40 countries, he is very familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world. Mr. Thoelke has spoken widely regarding the current landscape of clinical trial recruitment and its effect on drug development timelines. He is active in pursuing novel technologies and strategies to move the current clinical drug development paradigm away from anecdotal strategy to a more focused evidence-based strategy.

The deadline for registration is Tuesday March 24, 2009. Registration information can be found at: http://www.fxconferences.com/Beyond-Global-Feasibility-An-Evidence-Based-Approach-to-Creating-Realistic-Development-Timelines-P300.aspx .

About PRA International

PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Oncology, CNS, Respiratory/Allergy, Cardiovascular and Infectious Diseases, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Toxic Chemicals in Childrens Bath Products Trigger International Outcry
2. Barriers to diabetes care include restaurants and high-risk lifestyles, says international review
3. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
4. International Trachoma Initiative and the Task Force for Child Survival and Development Announce New Merger to Eliminate Blinding Trachoma and Fight Against Other Neglected Tropical Diseases
5. Mobile Massage Team Attending International Special Events Society Greater Philadelphia Chapter Industry Showcase - FRESH! 2009
6. Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International
7. Relsys International Announces the Release of the Argus Safety(TM) Suite 5.0
8. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
9. Irish-Owned Heritage Casket Company Strikes Multi-Million-Dollar Partnership Deal With Pennsylvanias Matthews International
10. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
11. Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location ... now offering laser dental treatments. Dental lasers are safe and effective options, and can ... options and can improve the overall quality of care. , Dr. Hamid Reza of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), ... medical education conference for clinicians who manage some of the most difficult-to-treat forms ... , The program will be led by co- chairs Dr. John Marshall, chief ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... in order to improve teacher quality, the field must first improve teacher preparation ... popular reform to the next” and that decades of input- and outcome-based research ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... 2017  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... fourth quarter and year ended December 31, 2016. ... progress for Orexigen, beginning with the re-acquisition of the ... March, the team at Orexigen demonstrated remarkable focus, executing ... and strengthened our Company while rewarding us full control ...
Breaking Medicine Technology: